The 2010 NHANES study suggests that the overall prevalence of osteoporosis (OP) in the USA is ~10% or 10.2 million older adults (> 50 yrs) had osteoporosis.

Yesterday the U.S. Food and Drug Administration approved a new biosimilar, Erelzi, (etanercept-szzs), for the same multipile indications as the originator Enbrel, including rheumatoid arthritis, plaque psoriasis, Erelzi, will be generically labelled as etanercept-szzs.

Dr. Jack Cush reviews news and journal reports from the past week on RheumNow.com.

Current guidelines regarding the use of biologics in patients who have previously had a malignancy are based more on opinion than evidence.

Is the occurrence of a fragility fracture a missed opportunity to reduce exposure to prescription drugs associated with fracture risk?

Researchers from Germany have analyzed their large prospective rheumatoid arthritis (RA) registry to address whether being on biologic therapies leads to poorer outcomes - namely sepsis or death, following a serious infection (SIE).

The goal in rheumatoid arthritis (RA) treatment is remission. But what level or method of remission is best?

A U.S. court has affirmed its decision that the patent for Johnson & Johnson's drug Remicade is invalid. This new ruling favors the intent of Celltrion and Pfizer, who are seeking to bring their biosimilar versions of infliximab to market in the near future.

Tobacco and chronic smoking is a major risk factor for the onset of rheumatoid arthritis (RA), and chronic smoking has been linked to severity of disease and lower DMARD response rates.

Rheumatologists are well-acquainted with the rules for hydroxychloroquine (HCQ) retinopathy screening: A) annual visits to the ophthalmologist and B) maintain HCQ doses at less than 6.5 mg/kg to avoid retinopathy.

Warnings of cancer, especially lymphoma, have accompanied the development and promotion of tumor necrosis factor inhbitors (TNFi) in the treatment of RA and other inflammatory disorders.

Circadian rhythms may be disrupted or become exaggerated in a variety of inflammatory conditions. For instance, interleukin-6 (IL-6) and IL-1 have a known circadian cycle to their production, but the same can not be said for TNF.

Infections are a concern for many when using tumor necrosis factor-α inhibitor (TNFi) therapy to treat inflammatory disorders. Even moreso in those at higher risk.

Patient-reported outcomes in rheumatoid arthritis (RA) correlate independently with measures of inflammation and structural damage on MRI scans, according to data from a longitudinal study.

Nerve growth factor (NGF) is a key modulator of pain perception,  Inhibitors of NGF are being studied in several chronic pain conditions, including osteoarthritis (OA).

Chingcuanco and coinvestigators have reported on their comparative analysis of biosimilars and their originator TNF inhibitors in the current issue of Annals of Internal Medicine.  (Citation source: http://buff.ly/2arTd1q)

Tumor necrosis factor (TNF) receptor-associated periodic syndrome (TRAPS) is an autosomal-dominant autoinflammatory disease resulting from mutations of the TNF super family receptor 1A (TNFRSF1A) gene.

Dr Jack Cush reviews this week's highlights from RheumNow.com.

Burmester and colleagues have published their review of the long-term outcomes and safety issues with the TNF inhibitor, adalimumab (ADA). The analysis included 15,132 patients exposed to adalimumab in global RA clinical trials.

From tofacitinib developmental trials in RA and psoriasis and adherence to T2T in early RA to a rheumatology pearl about dapsone and much more, here are the highlights of what you may have missed on RheumNow.com this week.